BRPI0507661A - método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo - Google Patents

método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo

Info

Publication number
BRPI0507661A
BRPI0507661A BRPI0507661-7A BRPI0507661A BRPI0507661A BR PI0507661 A BRPI0507661 A BR PI0507661A BR PI0507661 A BRPI0507661 A BR PI0507661A BR PI0507661 A BRPI0507661 A BR PI0507661A
Authority
BR
Brazil
Prior art keywords
active compound
bioavailability
therapeutically active
increasing bioavailability
prevention
Prior art date
Application number
BRPI0507661-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Markku Anttila
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507661(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of BRPI0507661A publication Critical patent/BRPI0507661A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
BRPI0507661-7A 2004-02-13 2005-01-14 método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo BRPI0507661A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene
PCT/FI2005/000018 WO2005077350A1 (en) 2004-02-13 2005-01-14 Method for enhancing the bioavailability of ospemifene

Publications (1)

Publication Number Publication Date
BRPI0507661A true BRPI0507661A (pt) 2007-07-17

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507661-7A BRPI0507661A (pt) 2004-02-13 2005-01-14 método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo

Country Status (23)

Country Link
US (5) US8236861B2 (OSRAM)
EP (1) EP1713458B1 (OSRAM)
JP (2) JP5577011B2 (OSRAM)
CN (1) CN1925847A (OSRAM)
AT (1) ATE387910T1 (OSRAM)
AU (1) AU2005211958B2 (OSRAM)
BE (1) BE2015C033I2 (OSRAM)
BR (1) BRPI0507661A (OSRAM)
CA (1) CA2556089C (OSRAM)
CY (2) CY1111014T1 (OSRAM)
DE (1) DE602005005165T2 (OSRAM)
DK (1) DK1713458T5 (OSRAM)
ES (1) ES2302177T3 (OSRAM)
FR (1) FR15C0041I2 (OSRAM)
HU (1) HUS1500030I1 (OSRAM)
LT (1) LTC1713458I2 (OSRAM)
LU (1) LU92736I2 (OSRAM)
MX (1) MXPA06009274A (OSRAM)
NO (2) NO337656B1 (OSRAM)
PL (1) PL1713458T3 (OSRAM)
PT (1) PT1713458E (OSRAM)
RU (1) RU2385716C2 (OSRAM)
WO (1) WO2005077350A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
SI1742618T1 (sl) 2004-05-04 2012-12-31 Hormos Medical Ltd. Tekoäśe oralne formulacije ospemifena
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
WO2007099410A2 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
EA023472B1 (ru) * 2005-11-28 2016-06-30 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
KR101510646B1 (ko) * 2007-02-14 2015-04-10 호르모스 메디칼 리미티드 치료적으로 유용한 트리페닐부텐 유도체의 제조 방법
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
DK3790548T3 (da) 2018-05-11 2023-11-13 Xenon Pharmaceuticals Inc Fremgangsmåder til forbedring af biotilgængeligheden og eksponeringen af en åbner af spændingsstyret kaliumkanal
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
TW202128162A (zh) 2019-11-08 2021-08-01 加拿大商再諾製藥公司 憂鬱症之治療方法
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
ES2255294T3 (es) * 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
US6219674B1 (en) * 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
CA2438816A1 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
PT1509215E (pt) 2002-06-06 2007-01-31 Hormos Medical Ltd Tratamento ou profilaxia da atrofia urogenital e seus sintomas em mulheres
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
DE602005005165T2 (de) 2009-04-30
US20140303259A1 (en) 2014-10-09
JP2014141533A (ja) 2014-08-07
ATE387910T1 (de) 2008-03-15
RU2006132719A (ru) 2008-03-20
RU2385716C2 (ru) 2010-04-10
FR15C0041I1 (OSRAM) 2015-07-17
PL1713458T3 (pl) 2008-08-29
NO20063960L (no) 2006-11-03
JP2007522190A (ja) 2007-08-09
JP6023119B2 (ja) 2016-11-09
WO2005077350A1 (en) 2005-08-25
FR15C0041I2 (fr) 2015-11-13
CA2556089C (en) 2013-04-02
AU2005211958A1 (en) 2005-08-25
DK1713458T5 (da) 2008-09-29
EP1713458B1 (en) 2008-03-05
CA2556089A1 (en) 2005-08-25
MXPA06009274A (es) 2007-04-16
US9241915B2 (en) 2016-01-26
CN1925847A (zh) 2007-03-07
AU2005211958B2 (en) 2010-11-25
EP1713458A1 (en) 2006-10-25
CY1111014T1 (el) 2015-06-11
US9855224B2 (en) 2018-01-02
NO337656B1 (no) 2016-05-23
DE602005005165D1 (de) 2008-04-17
US8470890B2 (en) 2013-06-25
LU92736I2 (fr) 2015-08-10
JP5577011B2 (ja) 2014-08-20
US20160101065A1 (en) 2016-04-14
NO20151603L (no) 2006-11-03
NO339190B1 (no) 2016-11-14
LTPA2015023I1 (lt) 2015-08-25
ES2302177T3 (es) 2008-07-01
US20130324614A1 (en) 2013-12-05
LTC1713458I2 (lt) 2017-06-26
BE2015C033I2 (OSRAM) 2024-08-08
PT1713458E (pt) 2008-05-07
DK1713458T3 (da) 2008-07-07
US20050182143A1 (en) 2005-08-18
US20120270952A1 (en) 2012-10-25
US8236861B2 (en) 2012-08-07
HUS1500030I1 (hu) 2015-08-28
US8772353B2 (en) 2014-07-08
CY2015027I1 (el) 2016-04-13
CY2015027I2 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
BRPI0507661A (pt) método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo
SG10201909122QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
EA200801602A1 (ru) Эмульсия
BRPI0606736A2 (pt) combinação de compostos e esteróides de metilxantina para tratar doenças respiratórias crÈnicas
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
MY153852A (en) Galenic formulations of organic compounds
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2007098264A3 (en) Use of rasagiline for the treatment of multiple system atrophy
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
BRPI0517227B8 (pt) comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
DK1305014T3 (da) Anvendelse af (deaminohydroxy)toremifen til behandling af vaginal törhed eller seksuel dysfunktion hos kvinder under eller efter menopausen
EA201170405A1 (ru) Монотерпены для лечения заболеваний дыхательных путей, в частности, бронхолегочных заболеваний
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
IL164528A0 (en) Method for inhibition of atrophy or for treatment or prevention of atrophy related symptoms in women
WO2009037584A3 (en) Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2353358C2 (ru) Производные прегабалина для лечения приливов
ECSP11010941A (es) Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual
JP2008533079A5 (OSRAM)
WO2010041889A3 (en) Pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease
WO2010047559A3 (ko) 방출성이 제어된 약제학적 제제
EA201592159A1 (ru) Применение тиазолопиримидинона для лечения воспалительного заболевания кишечника
RU2004133450A (ru) Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]